Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | HWEL | Class A Common Stock | Conversion of derivative security | +6.25M | 6.25M | Jul 21, 2023 | Direct | F1, F2 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | HWEL | Class B Common Stock | Conversion of derivative security | -6.25M | -100% | 1 | Jul 21, 2023 | Class A Common Stock | 6.25M | Direct | F1, F2 |
Id | Content |
---|---|
F1 | The shares of Class B common stock, par value $0.0001 per share, of the Issuer ("Class B Common Stock") are convertible into an equal number of shares of Class A common stock, par value $0.0001 per share, of the Issuer ("Class A Common Stock"). On July 21, 2023, Healthwell Acquisition Corp. I Sponsor LLC (the "Sponsor") elected to convert 6,249,999 shares of their Class B Common Stock into an equal number of shares of Class A Common Stock. |
F2 | The securities are held directly by the Sponsor and indirectly by Alyssa Rapp, who serves as the Chief Executive Officer and a director of the Issuer, and John L. MacCarthy, who serves as a director of the Issuer, and who directly control the Sponsor. Certain of the Issuer's other directors and officers hold economic interests in the Sponsor and pecuniary interests in certain of the securities held by the Sponsor. Each of Ms. Rapp and Mr. MacCarthy and such other directors and officers disclaims beneficial ownership of such securities except to the extent of his or her pecuniary interest therein. |